Experts: FDA Should Further Loosen, Clarify Mifepristone Restrictions

By Beth Wang / June 24, 2022 at 7:02 PM
Legal scholars argue FDA should further loosen or remove its prescribing and dispensing requirements for the abortion pill mifepristone to facilitate access to abortion care now that the Supreme Court has overturned Roe v. Wade and left abortion policy up to the states. The experts say FDA should clarify how pharmacies can become certified to dispense the pill; stop requiring prescribers to register as mifepristone providers, since that could make them the target of boycotts, protests and violence; and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.